Kong Yu-Gyeong, Park Ji Hyun, Park Jun-Young, Yu Jihion, Lee Joonho, Park Se-Ung, Jeong In Gab, Hwang Jai-Hyun, Kim Hee Yeong, Kim Young-Kug
Department of Anesthesiology and Pain Medicine, Hangang Sacred Heart Hospital, Hallym University College of Medicine Department of Anesthesiology and Pain Medicine Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Medicine (Baltimore). 2018 Jun;97(26):e11338. doi: 10.1097/MD.0000000000011338.
Mannitol, an osmotic diuretic, has been used to prevent acute kidney injury (AKI). However, studies have found divergent effects of intraoperative mannitol administration on postoperative AKI. We therefore evaluated the effects of intraoperative mannitol administration on AKI after robot-assisted laparoscopic radical prostatectomy (RALP) in prostate cancer patients.A total of 864 patients who underwent RALP were divided into mannitol (administered at 0.5 g/kg) and no-mannitol groups. Demographics, cancer-related data, preoperative laboratory values, intraoperative data, and postoperative outcomes such as AKI, chronic kidney disease at 12 months postoperation, duration of hospital stay, and intensive care unit admission rate and duration of stay were compared between the 2 groups using propensity score matching analysis. To determine the risk factors for AKI after RALP, univariate and multivariate logistic regression analyses were performed. Postoperative AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria.After performing 1:1 propensity score matching, the mannitol and no-mannitol groups included 234 patients each. The overall incidence of AKI after RALP was 5.1% and was not significantly different between the no-mannitol and mannitol groups in the propensity score-matched patients (13 [5.6%] vs. 11 [4.7%], P = .832). Univariate logistic regression analysis revealed that body mass index and operative time were associated with AKI in 864 patients who underwent RALP. However, intraoperative mannitol administration was not associated with AKI after RALP (P = .284). Multivariate logistic regression analysis revealed that operative time was significantly associated with AKI after RALP (odds ratio = 1.013, P = .001). The incidence of chronic kidney disease (13 [5.6%] vs. 12 [5.1%], P = 1.000) and other postoperative outcomes were not also significantly different between the no-mannitol and mannitol groups in the propensity score-matched patients.Intraoperative mannitol administration has no beneficial effect on the prevention of AKI after RALP in prostate cancer patients. This result provides useful information for clinical practice guidelines regarding intraoperative mannitol use.
甘露醇是一种渗透性利尿剂,已被用于预防急性肾损伤(AKI)。然而,研究发现术中给予甘露醇对术后AKI的影响存在差异。因此,我们评估了术中给予甘露醇对前列腺癌患者机器人辅助腹腔镜根治性前列腺切除术(RALP)后AKI的影响。
共有864例行RALP的患者被分为甘露醇组(按0.5 g/kg给药)和非甘露醇组。使用倾向评分匹配分析比较两组患者的人口统计学、癌症相关数据、术前实验室检查值、术中数据以及术后结局,如AKI、术后12个月的慢性肾脏病、住院时间、重症监护病房入住率及住院时间。为确定RALP后AKI的危险因素,进行了单因素和多因素逻辑回归分析。术后AKI根据《改善全球肾脏病预后组织》标准定义。
进行1:1倾向评分匹配后,甘露醇组和非甘露醇组各纳入234例患者。RALP后AKI的总体发生率为5.1%,在倾向评分匹配的患者中,非甘露醇组和甘露醇组之间无显著差异(13例[5.6%] vs. 11例[4.7%],P = 0.832)。单因素逻辑回归分析显示,在864例行RALP的患者中,体重指数和手术时间与AKI相关。然而,术中给予甘露醇与RALP后AKI无关(P = 0.284)。多因素逻辑回归分析显示,手术时间与RALP后AKI显著相关(比值比 = 1.013,P = 0.001)。在倾向评分匹配的患者中,非甘露醇组和甘露醇组之间慢性肾脏病的发生率(13例[5.6%] vs. 12例[5.1%],P = 1.000)及其他术后结局也无显著差异。
术中给予甘露醇对前列腺癌患者RALP后预防AKI无有益作用。该结果为关于术中使用甘露醇的临床实践指南提供了有用信息。